Trade Mark Journal No.2024/041 11 October 2024

UK00004107349 2 October 2024 (5,42)

DEL-BRAX

International priority date claimed: 25 June 2024 (United States of America) (98617274)

Class 5: Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders.
Class 42: Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology.

Avidity Biosciences, Inc.

Representative: Abion UK Limited